Literature DB >> 9804290

Modification of [3H]MK801 binding to rat brain NMDA receptors after the administration of a convulsant drug and an adenosine analogue: a quantitative autoradiographic study.

L Giraldez1, E Girardi.   

Abstract

Specific [3H]MK801 binding to rat brain NMDA receptors after the administration of the convulsant drug 3-mercaptopropionic acid (MP) and the adenosine analogue cyclopentyladenosine (CPA) was studied by means of a quantitative autoradiographic method. MP administration (150 mg/kg, i.p.) caused significant decreases in [3H]MK801 binding in several hippocampus subareas and layers, mainly in CA1 and CA3 at seizure (11-27%) and postseizure (8-16%) and in cerebral occipital cortex at seizure (18-22%). In nucleus accumbens, a rise was observed at postseizure (44%) and a tendency to increase at seizure (24%). CPA (2mg/kg, i.p.) decreased ligand binding in hippocampus (CAI, CA2, CA3) (17-22%) and in occipital cerebral cortex (18-24%). When CPA was administered 30 minutes before MP (which delayed seizure onset) and rats were sacrificed at seizure, decreases in [3H]MK801 binding in several layers of CA1 and CA3 of hippocampus (11-27%) and in CA1, CA2, CA3 (24-35%) after CPA+MP postseizure, and an increase in CA2 after CPA and CPA+MP postseizure (20-34%), were observed. A drop was found in the occipital subarea (18-24%) after CPA and in the frontal and occipital subarea after CPA+MP postseizure (24-34%) while no changes were observed in any treatment involving the other cerebral cortex regions, thalamic nuclei, caudate putamen and olfactory tubercle. These results show that [3H]MK801 binding changes according to drug treatment and the area being studied, thus indicating a different role in seizure activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9804290     DOI: 10.1023/a:1020708603495

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  50 in total

1.  Activation of interneurons at the stratum oriens/alveus border suppresses excitatory transmission to apical dendrites in the CA1 area of the mouse hippocampus.

Authors:  Y Yanovsky; O A Sergeeva; T F Freund; H L Haas
Journal:  Neuroscience       Date:  1997-03       Impact factor: 3.590

Review 2.  Excitatory amino acid receptors in the brain: membrane binding and receptor autoradiographic approaches.

Authors:  A B Young; G E Fagg
Journal:  Trends Pharmacol Sci       Date:  1990-03       Impact factor: 14.819

3.  Psychostimulants depress excitatory synaptic transmission in the nucleus accumbens via presynaptic D1-like dopamine receptors.

Authors:  S M Nicola; S B Kombian; R C Malenka
Journal:  J Neurosci       Date:  1996-03-01       Impact factor: 6.167

Review 4.  Endogenous control of epilepsy: the nigral inhibitory system.

Authors:  A Depaulis; M Vergnes; C Marescaux
Journal:  Prog Neurobiol       Date:  1994-01       Impact factor: 11.685

5.  Citrate synthase activity increases in homogenates of the cerebral cortex from rats treated with the convulsant 3-mercaptopropionic acid.

Authors:  E Girardi; G R Lores Arnaiz
Journal:  Neurochem Int       Date:  1985       Impact factor: 3.921

6.  Glutamate binding to brain membranes is increased in pentylenetetrazole-kindled rats.

Authors:  H Schröder; A Becker; B Lössner
Journal:  J Neurochem       Date:  1993-03       Impact factor: 5.372

7.  Changes of NMDA receptor binding in spontaneously epileptic rat and parent strains.

Authors:  I Mitsuyoshi; M Ito; Y Shirasaka; H Mikawa; T Serikawa; J Yamada
Journal:  Neurochem Res       Date:  1993-11       Impact factor: 3.996

Review 8.  Neurochemical aspects of the N-methyl-D-aspartate receptor complex.

Authors:  Y Yoneda; K Ogita
Journal:  Neurosci Res       Date:  1991-02       Impact factor: 3.304

9.  Regional variations in [3H]MK801 binding to rat brain N-methyl-D-aspartate receptors.

Authors:  I J Reynolds; A M Palmer
Journal:  J Neurochem       Date:  1991-05       Impact factor: 5.372

10.  Excitatory effect of adenosine on neurotransmission is due to increase of transmitter release in the hippocampal slices.

Authors:  Y Okada; T Sakurai; M Mori
Journal:  Neurosci Lett       Date:  1992-08-17       Impact factor: 3.046

View more
  7 in total

1.  3-mercaptopropionic acid-induced seizures decrease NR2B expression in Purkinje cells: cyclopentyladenosine effect.

Authors:  E Girardi; J Auzmendi; N Charó; M B Gori; M Castro
Journal:  Cell Mol Neurobiol       Date:  2010-07-13       Impact factor: 5.046

2.  Striatum adenosine A2 receptors are modified during seizure: effect of cyclopentyladenosine administration.

Authors:  L Giraldez; F Zanetti; E Girardi
Journal:  Neurochem Res       Date:  1999-10       Impact factor: 3.996

3.  Seizure activity produces differential changes in adenosine A1 receptors within rat hippocampus.

Authors:  G Vanore; L Giraldez; G Rodríguez de Lores Arnaiz; E Girardi
Journal:  Neurochem Res       Date:  2001-03       Impact factor: 3.996

4.  3-Mercaptopropionic acid-induced repetitive seizures increase GluN2A expression in rat hippocampus: a potential neuroprotective role of cyclopentyladenosine.

Authors:  María Belén Gori; Elena Girardi
Journal:  Cell Mol Neurobiol       Date:  2013-06-08       Impact factor: 5.046

5.  Astrocytic response in hippocampus and cerebral cortex in an experimental epilepsy model.

Authors:  Elena Girardi; Alberto Javier Ramos; Gabriela Vanore; Alicia Brusco
Journal:  Neurochem Res       Date:  2004-02       Impact factor: 3.996

6.  The NMDAR subunit NR2B expression is modified in hippocampus after repetitive seizures.

Authors:  J Auzmendi; N González; Elena Girardi
Journal:  Neurochem Res       Date:  2008-08-27       Impact factor: 3.996

7.  Differential expression of cerebellar metabotropic glutamate receptors mGLUR2/3 and mGLUR4a after the administration of a convulsant drug and the adenosine analogue cyclopentyladenosine.

Authors:  Elena Silvia Girardi; Juan Canitrot; Marta Antonelli; Nélida N González; Héctor Coirini
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 4.414

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.